Jounce shares crash after it abandons immunotherapy combination trialShares in Jounce Therapeutics are down sharply after it emerged that its immunotherapy combination with Bristol-Myers Squibb’s Yervoy Share XJounce shares crash after it abandons immunotherapy combination trialhttps://pharmaphorum.com/news/jounce-shares-crash-after-it-abandons-immunotherapy-combination-trial/
Jounce set to make first biotech IPO of 2017Massachusetts-based company will test the waters for biotech sector Share XJounce set to make first biotech IPO of 2017https://pharmaphorum.com/news/jounce-gets-early-lead-2017-biotech-ipos/